Multi-target combinatory strategy to overcome tumor immune escape

Area of Science:

• Oncology
• Immunology

Background:

• Immune therapy is a key cancer treatment modality.
• Immune checkpoint inhibitors (ICIs) like ipilimumab and PD1/PD-L1 targeting antibodies have been approved.
• A significant portion of patients exhibit resistance to current ICI monotherapy.

Purpose of the Study:

• To review the progression of multiple immune checkpoints and their inhibitors.
• To discuss the advantages of combination immune checkpoint inhibitor therapy.
• To address the risks of immune-related adverse events associated with combination therapy.

Main Methods:

• Literature review of immune checkpoint inhibitors.
• Focus on combination therapy of multiple immune checkpoints.
• Analysis of treatment advantages and adverse events.

Main Results:

• Multiple immune checkpoints and inhibitors have been identified.
• Combination therapy presents a potential strategy to overcome resistance to monotherapy.
• Understanding risks associated with combination therapy is crucial.

Conclusions:

• Combination immune checkpoint inhibitor therapy is an emerging strategy for resistant cancers.
• Further research is needed to optimize combination regimens and manage adverse events.
• This approach holds promise for improving patient outcomes in solid tumors.